interruption is one of the aims of present research efforts towards eradication, to alleviate HIV-1 burden, drug toxicity, and costs. Initiation of ART during primary HIV-1 infection (PHI) is associated with reduced size and diversity of viral reservoirs and enhanced immune preservation, relative to chronic infection. This is reflected in prolonged aviremia in a minority of early treated seroconverters who discontinue ART [1] [2] [3] . Elucidating the underlying mechanisms may facilitate the development of curative therapy. In this study, we describe the favorable outcome of a woman who initiated ART during a severe acute retroviral syndrome. She stopped therapy 6 years later and has since experienced a decade of apparent spontaneous control. We report the virological and immunological features of this unusual case.
METHODS

Quantification of the Human Immunodeficiency Virus-1 Reservoir
Written permission was obtained from the patient for reporting of her case. The patient was infected with a clade C virus. During 17 years of follow-up, HIV-1 viremia was quantified with several validated assays, which included non-B primers in accordance with laboratory and clinical practice at the time. Low copy viremia was determined as described in Supplementary Methods. Quantification of cell-associated HIV-1 DNA in blood sampled during 2007-2013 was performed as described previously [4, 5] . Integrated HIV-1 DNA was determined in samples from 2013 onwards by Alu-HIV polymerase chain reaction (PCR), in addition to quantification of total and episomal 2-long terminal repeat (LTR) circles [6, 7] (Supplementary Methods).
Human Leukocyte Antigen Typing
The patient's human leukocyte antigen (HLA) type was determined by ARMS-PCR using sequence-specific primers as follows: HLA A*0101, *3001, B*4901, Cw*0701, DRB1 *0804, DQB1 *0301 (homozygous at HLA-B, Cw, DR, and DQ loci).
Assessment of Human Immunodeficiency Virus-1-Specific Cellular Immune Responses
T-cell responses to the entire HIV-1 proteome were assessed initially using pools of clade B 15-mer peptides overlapping by 11 amino acids and, subsequently, corresponding overlapping clade C 18-mers, (NIH AIDS Reagent Program, final concentration 2 µg/mL) in ex vivo interferon (IFN)-γ enzymelinked immunospot (ELISPOT) assays, as described previously [8] . Further details are given in Supplementary Methods. Table 1) . Ex vivo CD8 + T-cell viral inhibitory activity was determined using a viral inhibition assay as described previously [8] . Primary CD4 + T cells were superinfected with laboratory-adapted or primary virus isolates (Programme EVA Centre for AIDS Reagents, National Institute for Biological Standards and Control) at a multiplicity of infection of 0.01: HIV-1BaL (CCR5-tropic, clade B), HIV-1IIIB (CXCR4-tropic, clade B), and HIV-1C (CCR5-tropic, clade C).
RESULTS
Case Report
A 23-year-old woman of Ethiopian origin presented in 1997 with a 3-week history of fever, sore throat, rash, lymphadenopathy, myalgia, and arthralgia. Her HIV-1 antibody test was positive with incomplete reactivity on HIV Western blot. She had tested HIV-1 seronegative in 1996. Three consecutive CD4 + Tcell counts were <200 cells/mm 3 , and her viral load was initially >750 000 HIV-1 copies (c)/mL. The patient started zidovudine 250 mg twice daily, lamivudine 150 mg twice daily, and indinavir 800 mg 3 times a day. The latter was subsequently switched to ritonavir 600 mg twice daily because of intolerance. She remained viremic (up to 94 400 HIV-1 c/mL) while on treatment and required intensification (twice daily saquinavir 400 mg and ritonavir 400 mg), which was initiated in May 1998. Suppression of viremia <50 HIV-1 c/mL was not achieved until approximately 1 year later, but it was sustained for nearly 5 years thereafter, at which point ART was stopped at the patient's request. The pre-ART discontinuation CD4 + T-cell count was 863 cells/mm 3 (30%), with a CD4 + /CD8 + T-cell ratio of 0.7.
The patient has since remained asymptomatic with undetectable viremia, normal CD4 + T-cell counts, and a CD4 + /CD8 + T-cell ratio >1 during 10 years of follow-up off ART (Figure 1 Figure 1C and D) . Efficient suppression of the clade C isolate was also observed at a lower CD8 + /CD4 + T-cell ratio (1:10%-59% vs 30% for IIIB and 22%
for BaL). Antiviral activity against the patient's endogenous virus was equivalent to HIV-1C at both CD8 + /CD4 + T cell ratios (70.5% and 52.3% for 1:1 and 1:10 ratios, respectively) (Figure 1C and D) .
Broad CD4 + T-Cell Responses Target Vulnerable Regions Within Gag
Interferon-γ-secreting CD8 + and CD4 + T cells were predominantly targeted to 14 regions within HIV-1 Gag, Pol, and Nef ( Figure 1E , Supplementary Figure 1A -C). T-cell responses were also targeted to 7 vulnerable (beneficial) regions within the clade B and C viral proteomes (Supplementary Table 1) and were predominantly CD4 + T cell-mediated ( Figure 1E and 1F, Supplementary Figure 1D) . 
DISCUSSION
This case shows that long-term control of viremia and normalization of immune parameters may follow discontinuation of prolonged ART initiated at PHI, even in the context of persistent viremia of nearly 5 log 10 HIV-1 c/mL during initial ART and the absence of favorable HLA alleles. Such features would typically preclude long-term nonprogressor status [10] .
Salgado et al and Sáez-Cirión et al have reported post-ART virological control after treatment during PHI, despite initial viremia of up to 7 log 10 c/mL. The majority of these subjects had an inducible viral reservoir, indicating that they were infected with replication-competent viruses [2, 3] . We confirmed that our patient's CD4 + T cells were susceptible to superinfection with R5-and X4-tropic viruses, with similar frequencies of infected cells to those we have observed following in vitro infection of healthy donor PBMCs [11] . Furthermore, we were able to detect outgrowth of endogenous HIV-1 in CD4 + T cells after in vitro activation, albeit at a low level, indicating a persistent inducible reservoir. Although posttreatment controllers thus show some virological similarities with patients with spontaneous elite control of HIV-1, an intriguing difference is the lower activation status in the former [12] . Our patient also showed posttreatment control of immune activation: the frequency of CD38 + CD8 + T cells has remained within normal limits throughout follow up.
With regard to HIV-specific immune responses, this case is distinct from previously described posttreatment controllers [2, 3] . CD8 + T-cell inhibition of both heterologous and autologous HIV-1 replication was detected at a low CD8 + /CD4 + cell ratio.
Although these responses were less potent than was observed in HIV controllers (median 85%, n = 20) [8, 13] , they nevertheless surpassed that of chronic ART-treated individuals who were virologically suppressed for ≥1 year (median 24%, n = 42; our unpublished observations). This result suggests that our patient's CD8 + T-cell antiviral responses were likely to be a contributing factor to her virological control, rather than a consequence of it. The preserved and broad HIV-1-specific CD4 + T-cell responses observed in this patient are also particularly surprising when taking into account the profound CD4 + T-cell depletion ob- Figures 2-4 ). Furthermore, we were able to show that CD4 + T cells were targeted to multiple regions of vulnerability within Gag. Such responses have been associated with spontaneous control of viremia [9, 14] . It is not known whether this association is mediated by direct cytolytic mechanisms or indirectly, through provision of effective help to CD8 + T cells. This deserves further exploration. We also considered the possibility that humoral responses contributed to this patient's posttreatment control, because broadly neutralizing antibodies may play a role in controlling viremia in rare cases [15] . However, we found only low levels of neutralizing antibodies to heterologous virus in this case, when tested during the early period of aviremia in 2006-2007 (data not shown).
CONCLUSIONS
In conclusion, we have identified an atypical case of posttreatment control, which may have been achieved through very early ART during PHI combined with effective cell-mediated immune responses. Our data suggest that strategies aiming to induce such immune responses during early ART might influence posttreatment virological control.
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